146 related articles for article (PubMed ID: 1336489)
1. Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation.
Orengo G; Noviello E; Cimoli G; Pagnan G; Parodi S; Venturini M; Conte P; Schenone F; Conzi G; Russo P
Jpn J Cancer Res; 1992 Nov; 83(11):1132-6. PubMed ID: 1336489
[TBL] [Abstract][Full Text] [Related]
2. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
Utsugi T; Mattern MR; Mirabelli CK; Hanna N
Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of antineoplastic effects by the combination of recombinant human tumor necrosis factor and mitoxantrone on primary culture of human ovarian cancer cells.
Cimoli G; Valenti M; Venturini M; Conte P; Russo P
Anticancer Res; 1992; 12(5):1411-4. PubMed ID: 1444198
[TBL] [Abstract][Full Text] [Related]
5. Potentiation by tumor necrosis factor of mitoxantrone cytotoxicity to human ovarian cancer cell lines.
Russo P; Parodi S; Billi G; Oliva C; Venturini M; Noviello E; Conte P
Jpn J Cancer Res; 1992 Jul; 83(7):684-7. PubMed ID: 1517145
[TBL] [Abstract][Full Text] [Related]
6. Circumvention of atypical multidrug resistance with tumor necrosis factor.
Cimoli G; Valenti M; Parodi S; De Sessa F; Russo P
Jpn J Cancer Res; 1994 Feb; 85(2):135-8. PubMed ID: 8144394
[TBL] [Abstract][Full Text] [Related]
7. Sister-chromatid exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: correlations with the formation of DNA double-strand breaks.
Noviello E; Aluigi MG; Cimoli G; Rovini E; Mazzoni A; Parodi S; De Sessa F; Russo P
Mutat Res; 1994 Nov; 311(1):21-9. PubMed ID: 7526171
[TBL] [Abstract][Full Text] [Related]
8. Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: potentiation of mitoxantrone cytotoxicity.
Vigani A; Chiara S; Miglietta L; Repetto L; Conte PF; Cimoli G; Morelli L; Billi G; Parodi S; Russo P
Gynecol Oncol; 1991 Apr; 41(1):52-5. PubMed ID: 2026360
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells.
Nakaya K; Chou S; Kaneko M; Nakamura Y
Jpn J Cancer Res; 1991 Feb; 82(2):184-91. PubMed ID: 1848545
[TBL] [Abstract][Full Text] [Related]
10. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Kaufmann SH
Cancer Res; 1991 Feb; 51(4):1129-36. PubMed ID: 1705167
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
12. Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells.
Katz EJ; Vick JS; Kling KM; Andrews PA; Howell SB
Eur J Cancer; 1990; 26(6):724-7. PubMed ID: 2168194
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells.
Cortés F; Piñero J
Cancer Chemother Pharmacol; 1994; 34(5):411-5. PubMed ID: 8070008
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications.
Valenti M; Cimoli G; Parodi S; Mariani GL; Venturini M; Conte P; Russo P
Eur J Cancer; 1993; 29A(8):1157-61. PubMed ID: 8518027
[TBL] [Abstract][Full Text] [Related]
15. Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells.
Kyprianou N; Alexander RB; Isaacs JT
J Natl Cancer Inst; 1991 Mar; 83(5):346-50. PubMed ID: 1847434
[TBL] [Abstract][Full Text] [Related]
16. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
Jensen PB; Sørensen BS; Demant EJ; Sehested M; Jensen PS; Vindeløv L; Hansen HH
Cancer Res; 1990 Jun; 50(11):3311-6. PubMed ID: 2159380
[TBL] [Abstract][Full Text] [Related]
17. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II.
Alexander RB; Nelson WG; Coffey DS
Cancer Res; 1987 May; 47(9):2403-6. PubMed ID: 2436763
[TBL] [Abstract][Full Text] [Related]
18. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Epstein RJ; Smith PJ
Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
[TBL] [Abstract][Full Text] [Related]
19. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
20. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.
D'Arpa P; Beardmore C; Liu LF
Cancer Res; 1990 Nov; 50(21):6919-24. PubMed ID: 1698546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
